Navigation Links
Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
Date:9/10/2009

HORSHAM, Pa., Sept. 10 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

Centocor Ortho Biotech is evaluating the FDA's letter and will respond to the agency as quickly as possible.

The sNDA for DOXIL was submitted to the FDA in September 2008. DOXIL currently is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after prior platinum-based therapy. DOXIL in combination with bortezomib is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. DOXIL is also indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.

DOXIL is marketed in the United States by Centocor Ortho Biotech Products, L.P., and in Israel by Janssen-Cilag. Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market the medication as CAELYX throughout the rest of the world, excluding Japan and Israel. For more information about DOXIL, please visit www.DOXIL.com.

IMPORTANT SAFETY INFORMATION

BOXED WARNINGS:

Cardiotoxicity, infusion reaction, myelosuppression, liver impairment, substitution

  • The use of DOXIL may lead to cardiac toxicity. Myocardial damage may lead to congestive heart failure and may occur as the total cumulative do
    '/>"/>

SOURCE Centocor Ortho Biotech Products, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
6. GeneNews provides Centocor access to its osteoarthritis program
7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
8. Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
9. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
10. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
11. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... , Dec. 11, 2014 Research and Markets ... addition of the "Glucose Sensors: the Next ... http://photos.prnewswire.com/prnh/20130307/600769 The ... designs is giving hope for a better future ... monitors that can measure glucose levels accurately and ...
(Date:12/13/2014)... and SAN ANTONIO , Dec. 12, ... announced the presentation of data at the San Antonio ... study evaluating epoetin alfa plus best supportive care (BSC) ... with metastatic breast cancer receiving standard chemotherapy. This non-inferiority ... to rule out a 15 percent or greater increase ...
(Date:12/12/2014)... Graphite Metallizing Corporation, the manufacturer of ... process equipment, has appointed Kirk Staller as Sales Engineering ... Staller holds a B.S. degree from Purdue University and ... place, much of it with a manufacturer of centrifugal ... office. , “We are pleased to have ...
(Date:12/12/2014)... 2014 Electronic Data Interchange (EDI) ... management and supply chain management to depend from ... The benefits associated with the use of EDI ... transactions has helped improve the acceptance of this ... market data tables and 107 figures spread through ...
Breaking Biology Technology:Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Kirk Staller Joins Graphite Metallizing Corporation 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 3The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 4
... Ill., July 29 The Board of,Directors of Baxter ... dividend of $0.2175 per share of Baxter common stock., ... rate, which was,increased earlier this year by 30 percent. ... shareholders of record as of September 10,2008., Baxter ...
... an Antipsychotic Agent with Less Potential for ... Gain and Metabolic Risks, SAN DIEGO, July 29 ... that the United States Patent and,Trademark Office (USPTO) issued ... provide broad coverage for a pharmaceutical,composition of zonisamide in ...
... Nuvelo, Inc.,(Nasdaq: NUVO ) today announced ... in a,single-center, Phase 1 trial of recombinant, ... its Wnt Therapeutics Program. This,double-blind, placebo-controlled, single-ascending ... and pharmacokinetics of a single,intravenous (IV) administration ...
Cached Biology Technology:OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 3
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... toxins or nefarious germs, smaller and faster is better. ... especially when measurements by different instruments must give the ... standarda culmination of years of research at the National ... from handheld chemical detectors can be compared, apples-to-apples. ...
... of the most species-rich ant genera, latest research has stripped ... species- Paratrechina longicornis . This particular ant is one ... tropical and subtropical location on the planet due to accidental ... invasive ant species. A recent review of the genus in ...
... news release is available in German . ... on a course of treatment, tests can be carried out ... is likely to be effective. But the time-consuming and expensive ... Collaborating with DITABIS Digital Biomedical Imaging Systems AG and scientists ...
Cached Biology News:New spectrometry standard for handheld chemical detectors aids first responders 2The most widespread ant and its new relative: A revision of the genus Paratrechina 2A cost-effective way toward personalized cancer drugs 2A cost-effective way toward personalized cancer drugs 3